...
首页> 外文期刊>Medicine. >The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset
【24h】

The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset

机译:microRNA-122在预测肝细胞癌患者预后中的临床意义:通过癌症基因组图谱数据集验证的荟萃分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Although the prognostic value of microRNA-122 (miR-122) for hepatocellular carcinoma (HCC) patients have been evaluated by numerous studies, the results of them were not completely consistent. The present study aims to comprehensively evaluate the predicting value of miR-122 on the prognosis of patients with HCC based on all eligible literatures. Methods: Numerous electronic databases (MEDLINE, Embase, Pubmed, Google Scholar, and China Biology Medicine disc) were applied to retrieve relevant studies. Overall survival (OS) and progression-free survival (PFS) were used as primary endpoints. All statistical analyses were performed by RevMan software version 5.3.5 and STATA software version 14.1. In addition, the results of this meta-analysis were validated by an independent dataset from the Cancer Genome Atlas (TCGA). Results: A total of 11 studies containing 1124 patients were included in this meta-analysis . The pooled results showed that low miR-122 expression in HCC tissues significantly associated with unfavorable OS (hazard ratio [HR] = 1.48, 95% confidence interval [CI] 1.22–1.80, P .001) and PFS (HR = 1.54, 95% CI 1.28–1.85, P .001) in patients with HCC. However, the expression level of miR-122 in blood did not have the ability in predicting OS (HR = 0.75, 95% CI 0.44–1.28, P = .29) and PFS (HR = 0.84, 95% CI 0.58–1.20, P = .33) of HCC. Subgroup analysis further indicated that low expression of miR-122 in tumor tissues predicted poor OS in HCC patients who received curative liver resection (HR = 2.00, 95% CI 1.08–3.70, P = .03). Analysis using TCGA dataset suggested that low miR-122 expression in HCC tissues was significantly associated with OS (HR = 1.61, 95% CI 1.13–2.27, P = .008) other than PFS (HR = 1.30, 95% CI 0.96–1.75, P = .09). Conclusion: Low miR-122 expression in HCC tissues was a reliable indicator for predicting the OS of HCC patients who underwent curative resection. Owing to the disagreement between this meta-analysis and the TCGA dataset, the predictive value of miR-122 in tissues for PFS needs to be verified by future well-designed studies with large sample size.
机译:背景:尽管已经通过大量研究评估了microRNA-122(miR-122)对肝细胞癌(HCC)患者的预后价值,但结果并不完全一致。本研究旨在根据所有符合条件的文献,全面评估miR-122对HCC患者预后的预测价值。方法:应用大量电子数据库(MEDLINE,Embase,Pubmed,Google Scholar和China Biology Medicine光盘)检索相关研究。总生存期(OS)和无进展生存期(PFS)被用作主要终点。所有统计分析均通过RevMan软件版本5.3.5和STATA软件版本14.1进行。此外,通过癌症基因组图谱(TCGA)的独立数据集验证了该荟萃分析的结果。结果:这项荟萃分析共纳入11项研究,包括1124例患者。汇总的结果显示,miR-122在肝癌组织中的低表达与OS不利(危险比[HR] = 1.48、95%置信区间[CI] 1.22-1.80,P <.001)和PFS(HR = 1.54,肝癌患者的95%CI 1.28–1.85,P <.001)。但是,血液中miR-122的表达水平无法预测OS(HR = 0.75,95%CI 0.44–1.28,P = 0.29)和PFS(HR = 0.84,95%CI 0.58–1.20, P = .33)。亚组分析进一步表明,肿瘤组织中miR-122的低表达预示了接受根治性肝切除的HCC患者的OS较差(HR = 2.00,95%CI 1.08–3.70,P = .03)。使用TCGA数据集的分析表明,除了PFS(HR = 1.30,95%CI 0.96-1.75)以外,HCC组织中低miR-122表达与OS(HR = 1.61,95%CI 1.13–2.27,P = .008)显着相关。 ,P = .09)。结论:肝癌组织中miR-122的低表达是预测治愈性肝癌患者OS的可靠指标。由于这种荟萃分析与TCGA数据集之间的分歧,miR-122在组织中对PFS的预测价值需要通过未来精心设计的大样本研究进行验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号